Generate a Pharmacodynamic Model of Oxytocin for Peripheral Analgesic Effects
Primary Purpose
Osteoarthritis, Knee
Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Oxytocin
Sponsored by
About this trial
This is an interventional basic science trial for Osteoarthritis, Knee
Eligibility Criteria
Inclusion Criteria:
- Male or female > 18 and < 75 years of age, Body Mass Index (BMI) <40.
- Generally in good health as determined by the Principal Investigator based on prior medical history, American Society of Anesthesiologists physical status 1, 2, or 3.
- For healthy volunteers, normal blood pressure (systolic 90-140 mmHg; diastolic 50-90 mmHg) resting heart rate 45-100 beats per minute) without medication. For knee arthritis subjects, normal blood pressure or, for those with hypertension, pressure controlled with anti-hypertensives and with a resting heart rate 45-100 beats per minute.
- Female subjects of child-bearing potential and those < 1 year post-menopausal, must be practicing highly effective methods of birth control such as hormonal methods (e.g., combined oral, implantable, injectable, or transdermal contraceptives), double barrier methods (e.g., condoms, sponge, diaphragm, or vaginal ring plus spermicidal jellies or cream), or total abstinence from heterosexual intercourse for a minimum of 1 full cycle before study drug administration.
Exclusion Criteria:
- Hypersensitivity, allergy, or significant reaction to any ingredient of Pitocin®
- Any disease, diagnosis, or condition (medical or surgical) that, in the opinion of the Principal Investigator, would place the subject at increased risk (active gynecologic disease in which increased tone would be detrimental e.g., uterine fibroids with ongoing bleeding), compromise the subject's compliance with study procedures, or compromise the quality of the data
- Women who are pregnant (positive result for serum pregnancy test at screening visit), women who are currently nursing or lactating, women that have been pregnant within 2 years
- Subjects with neuropathy, chronic pain, diabetes mellitus, or taking benzodiazepines or pain medications on a daily basis.
- Subjects with current or history of ventricular tachycardia, atrial fibrillation or prolonged QT interval.
- Subjects with past or current history of hyponatremia or at risk for hyponatremia; anyone taking thiazide diuretics, loop diuretics, combination diuretics, lithium, carbamazepine, enalapril, Ramipril, celecoxib, temazepam, gliclazide, glimepiride, glibenclamide, glipizide, omeprazole, pantoprazole, desmopressin, SSRI's, MAOI, or the recreational drug ecstasy.
- Subjects with a known latex allergy.
- Subjects with a pain score rating of 1 or less during the initial training session to a 5 minute heating of 45°C- 47 °C to the lower calf.
Sites / Locations
- Wake Forest Baptist HealthRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Oxytocin
Arm Description
Oxytocin administered by IV infusion
Outcomes
Primary Outcome Measures
Pharmacodynamics of heat pain after oxytocin
3 Minutes prior to the Oxytocin infusion Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Pharmacodynamics of heat pain after oxytocin
12 Minutes after the Oxytocin infusion is initiated Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Pharmacodynamics of heat pain after oxytocin
27 Minutes after the Oxytocin infusion is initiated Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Pharmacodynamics of heat pain after oxytocin
42 Minutes after the Oxytocin infusion is initiated Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Pharmacodynamics of heat pain after oxytocin
57 Minutes after the Oxytocin infusion is initiated Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Pharmacodynamics of heat pain after oxytocin
Simultaneously with the beginning of the Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Pharmacodynamics of heat pain after oxytocin
15 minutes after the initiation of the Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Pharmacodynamics of heat pain after oxytocin
30 minutes after the initiation of the Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Pharmacodynamics of heat pain after oxytocin
45 minutes after the initiation of the Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Pharmacodynamics of heat pain after oxytocin
60 minutes after the initiation of the Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Pharmacodynamics of heat pain after oxytocin
2 minutes after initiation of Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined before, during and after infusions in order to create a PD model and validate the PK/PD model. Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Pharmacodynamics of heat pain after oxytocin
17 minutes after initiation of Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined before, during and after infusions in order to create a PD model and validate the PK/PD model. Pain at the end of 5 minutes of heating the skin to 45 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Pharmacodynamics of heat pain after oxytocin
32 minutes after initiation of Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined before, during and after infusions in order to create a PD model and validate the PK/PD model. Pain at the end of 5 minutes of heating the skin to 45 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Pharmacodynamics of heat pain after oxytocin
47 minutes after initiation of Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined before, during and after infusions in order to create a PD model and validate the PK/PD model. Pain at the end of 5 minutes of heating the skin to 45 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Pharmacodynamics of heat pain after oxytocin
62 minutes after initiation of Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined before, during and after infusions in order to create a PD model and validate the PK/PD model. Pain at the end of 5 minutes of heating the skin to 45 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Pharmacodynamics of heat pain after oxytocin
5 minutes after the beginning of the Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined before, during and after infusions in order to create a PD model and validate the PK/PD model. Pain at the end of 5 minutes of heating the skin to 45 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Pharmacodynamics of heat pain after oxytocin
20 minutes after the beginning of the Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined before, during and after infusions in order to create a PD model and validate the PK/PD model. Pain at the end of 5 minutes of heating the skin to 45 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Pharmacodynamics of heat pain after oxytocin
35 minutes after the beginning of the Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined before, during and after infusions in order to create a PD model and validate the PK/PD model. Pain at the end of 5 minutes of heating the skin to 45 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Pharmacodynamics of heat pain after oxytocin
50 minutes after the beginning of the Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined before, during and after infusions in order to create a PD model and validate the PK/PD model. Pain at the end of 5 minutes of heating the skin to 45 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Pharmacodynamics of heat pain after oxytocin
65 minutes after the beginning of the Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined before, during and after infusions in order to create a PD model and validate the PK/PD model. Pain at the end of 5 minutes of heating the skin to 45 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Secondary Outcome Measures
Full Information
NCT ID
NCT04431206
First Posted
June 4, 2020
Last Updated
May 2, 2023
Sponsor
Wake Forest University Health Sciences
1. Study Identification
Unique Protocol Identification Number
NCT04431206
Brief Title
Generate a Pharmacodynamic Model of Oxytocin for Peripheral Analgesic Effects
Official Title
Generate a Pharmacodynamic Model of Oxytocin for Peripheral Analgesic Effects
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 4, 2020 (Actual)
Primary Completion Date
February 2024 (Anticipated)
Study Completion Date
February 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Wake Forest University Health Sciences
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a study of participants that will receive an intravenous (IV) infusion of oxytocin (naturally occurring hormone that is made in the brain).
In this study healthy volunteers and people with knee arthritis so severe that they may need joint replacement are recruited for a one day study. Each study participant will have an IV catheter placed. After placement of the IV catheter oxytocin will be given by IV infusion. Investigators will perform some tests to evaluate how oxytocin changes perceptions on the skin. Investigators will study a painful perception by placing a probe on the skin and heating it to 113 -117 degrees Fahrenheit (F) for 5 minutes. Each study participant will score any pain that is experienced on a 0 to 10 scale, and most people find that pain rises during the 5 minutes, but remains mild, usually around only 1 or 2 on the 0 to 10 scale. The 5 minute heating temperature will be determined according to the subjects pain rating during the screening visit.
The main goal of the study is to determine the effect of oxytocin during and after a fixed rate intravenous infusion on reduction in pain to a sustained heat stimulus in order to generate a model for peripheral analgesia.
Detailed Description
In this study healthy people or those with knee arthritis so severe that they may need joint replacement are recruited for a one day study. Study participants will come to the Clinical Research Unit (CRU) and one intravenous (IV) catheter will be inserted in the forearm for oxytocin infusion. Participants in this study will receive oxytocin at a steady rate for 30 minutes. This information will be analyzed by another group at Stanford University in the Pharmacokinetic/Pharmacodynamic (PK/PD) Core part of this application. Mathematics will be utilized to calculate how quickly oxytocin moves from the blood to where it reduces pain.
Investigators will also do a pain test to determine how much oxytocin reduces pain. For this Investigators will place a probe on the skin and heat it to 113 - 117 degrees for 5 minutes. Study participants will score any pain they feel on a 0 to 10 scale, and most people find that pain rises during the 5 minutes, but remains mild, usually around only 1 or 2 on the 0 to 10 scale.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis, Knee
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Model Description
Single group Oxytocin infusion
Masking
None (Open Label)
Allocation
N/A
Enrollment
38 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Oxytocin
Arm Type
Experimental
Arm Description
Oxytocin administered by IV infusion
Intervention Type
Drug
Intervention Name(s)
Oxytocin
Other Intervention Name(s)
Pitocin
Intervention Description
Oxytocin administered by IV infusion
Primary Outcome Measure Information:
Title
Pharmacodynamics of heat pain after oxytocin
Description
3 Minutes prior to the Oxytocin infusion Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Time Frame
3 minutes prior to Oxytocin infusion
Title
Pharmacodynamics of heat pain after oxytocin
Description
12 Minutes after the Oxytocin infusion is initiated Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Time Frame
12 minutes after the start of Oxytocin infusion
Title
Pharmacodynamics of heat pain after oxytocin
Description
27 Minutes after the Oxytocin infusion is initiated Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Time Frame
27 minutes after the start of Oxytocin infusion
Title
Pharmacodynamics of heat pain after oxytocin
Description
42 Minutes after the Oxytocin infusion is initiated Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Time Frame
42 minutes after the start of Oxytocin infusion
Title
Pharmacodynamics of heat pain after oxytocin
Description
57 Minutes after the Oxytocin infusion is initiated Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Time Frame
57 minutes after the start of Oxytocin infusion
Title
Pharmacodynamics of heat pain after oxytocin
Description
Simultaneously with the beginning of the Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Time Frame
Beginning of the Oxytocin infusion
Title
Pharmacodynamics of heat pain after oxytocin
Description
15 minutes after the initiation of the Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Time Frame
15 minutes after the start of Oxytocin infusion
Title
Pharmacodynamics of heat pain after oxytocin
Description
30 minutes after the initiation of the Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Time Frame
30 minutes after the start of Oxytocin infusion
Title
Pharmacodynamics of heat pain after oxytocin
Description
45 minutes after the initiation of the Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Time Frame
45 minutes after the start of Oxytocin infusion
Title
Pharmacodynamics of heat pain after oxytocin
Description
60 minutes after the initiation of the Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Time Frame
60 minutes after the start of Oxytocin infusion
Title
Pharmacodynamics of heat pain after oxytocin
Description
2 minutes after initiation of Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined before, during and after infusions in order to create a PD model and validate the PK/PD model. Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Time Frame
2 minutes after the beginning of the Oxytocin infusion
Title
Pharmacodynamics of heat pain after oxytocin
Description
17 minutes after initiation of Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined before, during and after infusions in order to create a PD model and validate the PK/PD model. Pain at the end of 5 minutes of heating the skin to 45 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Time Frame
17 minutes after the beginning of the Oxytocin infusion
Title
Pharmacodynamics of heat pain after oxytocin
Description
32 minutes after initiation of Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined before, during and after infusions in order to create a PD model and validate the PK/PD model. Pain at the end of 5 minutes of heating the skin to 45 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Time Frame
32 minutes after the beginning of the Oxytocin infusion
Title
Pharmacodynamics of heat pain after oxytocin
Description
47 minutes after initiation of Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined before, during and after infusions in order to create a PD model and validate the PK/PD model. Pain at the end of 5 minutes of heating the skin to 45 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Time Frame
47 minutes after the beginning of the Oxytocin infusion
Title
Pharmacodynamics of heat pain after oxytocin
Description
62 minutes after initiation of Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined before, during and after infusions in order to create a PD model and validate the PK/PD model. Pain at the end of 5 minutes of heating the skin to 45 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Time Frame
62 minutes after the beginning of the Oxytocin infusion
Title
Pharmacodynamics of heat pain after oxytocin
Description
5 minutes after the beginning of the Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined before, during and after infusions in order to create a PD model and validate the PK/PD model. Pain at the end of 5 minutes of heating the skin to 45 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Time Frame
5 minutes after the beginning of the Oxytocin infusion
Title
Pharmacodynamics of heat pain after oxytocin
Description
20 minutes after the beginning of the Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined before, during and after infusions in order to create a PD model and validate the PK/PD model. Pain at the end of 5 minutes of heating the skin to 45 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Time Frame
20 minutes after the beginning of the Oxytocin infusion
Title
Pharmacodynamics of heat pain after oxytocin
Description
35 minutes after the beginning of the Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined before, during and after infusions in order to create a PD model and validate the PK/PD model. Pain at the end of 5 minutes of heating the skin to 45 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Time Frame
35 minutes after the beginning of the Oxytocin infusion
Title
Pharmacodynamics of heat pain after oxytocin
Description
50 minutes after the beginning of the Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined before, during and after infusions in order to create a PD model and validate the PK/PD model. Pain at the end of 5 minutes of heating the skin to 45 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Time Frame
50 minutes after the beginning of the Oxytocin infusion
Title
Pharmacodynamics of heat pain after oxytocin
Description
65 minutes after the beginning of the Oxytocin infusion; Pain at the end of 5 minutes of heating the skin to 45 - 47 degrees C will be determined before, during and after infusions in order to create a PD model and validate the PK/PD model. Pain at the end of 5 minutes of heating the skin to 45 degrees C will be determined using a Verbal Pain scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to THE WORST PAIN IMAGINABLE. Heating temperature will be determined according to pain rating during screening visit.
Time Frame
65 minutes after the beginning of the Oxytocin infusion
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Male or female > 18 and < 75 years of age, Body Mass Index (BMI) <40.
Generally in good health as determined by the Principal Investigator based on prior medical history, American Society of Anesthesiologists physical status 1, 2, or 3.
For healthy volunteers, normal blood pressure (systolic 90-140 mmHg; diastolic 50-90 mmHg) resting heart rate 45-100 beats per minute) without medication. For knee arthritis subjects, normal blood pressure or, for those with hypertension, pressure controlled with anti-hypertensives and with a resting heart rate 45-100 beats per minute.
Female subjects of child-bearing potential and those < 1 year post-menopausal, must be practicing highly effective methods of birth control such as hormonal methods (e.g., combined oral, implantable, injectable, or transdermal contraceptives), double barrier methods (e.g., condoms, sponge, diaphragm, or vaginal ring plus spermicidal jellies or cream), or total abstinence from heterosexual intercourse for a minimum of 1 full cycle before study drug administration.
Exclusion Criteria:
Hypersensitivity, allergy, or significant reaction to any ingredient of Pitocin®
Any disease, diagnosis, or condition (medical or surgical) that, in the opinion of the Principal Investigator, would place the subject at increased risk (active gynecologic disease in which increased tone would be detrimental e.g., uterine fibroids with ongoing bleeding), compromise the subject's compliance with study procedures, or compromise the quality of the data
Women who are pregnant (positive result for serum pregnancy test at screening visit), women who are currently nursing or lactating, women that have been pregnant within 2 years
Subjects with neuropathy, chronic pain, diabetes mellitus, or taking benzodiazepines or pain medications on a daily basis.
Subjects with current or history of ventricular tachycardia, atrial fibrillation or prolonged QT interval.
Subjects with past or current history of hyponatremia or at risk for hyponatremia; anyone taking thiazide diuretics, loop diuretics, combination diuretics, lithium, carbamazepine, enalapril, Ramipril, celecoxib, temazepam, gliclazide, glimepiride, glibenclamide, glipizide, omeprazole, pantoprazole, desmopressin, SSRI's, MAOI, or the recreational drug ecstasy.
Subjects with a known latex allergy.
Subjects with a pain score rating of 1 or less during the initial training session to a 5 minute heating of 45°C- 47 °C to the lower calf.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Regina Curry, RN
Phone
336-716-4294
Email
RECURRY@WAKEHEALTH.EDU
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James C Eisenach, MD
Organizational Affiliation
Wake Forest University Health Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Wake Forest Baptist Health
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Regina Curry, RN
Phone
336-716-4294
Email
RECURRY@WAKEHEALTH.EDU
First Name & Middle Initial & Last Name & Degree
James C Eisenach, M.D.
12. IPD Sharing Statement
Learn more about this trial
Generate a Pharmacodynamic Model of Oxytocin for Peripheral Analgesic Effects
We'll reach out to this number within 24 hrs